pf-06823859
mAbexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started May 27, 2016 (NCT02766621)
Timeline
Indications
Mechanism of action
- Interferon betaINHIBITOR
IFNB1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297808 ↗
Also known as
- pf-06823859
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06698796 | Phase 3 | Jan 8, 2025 | Pfizer |
| NCT05879718 | Phase 2 | Jul 7, 2023 | Pfizer |
| NCT05895786 | Phase 3 | May 20, 2023 | Pfizer |
| NCT05192200 | Phase 2 | Dec 20, 2021 | Pfizer |
| NCT05037409 | Phase 1 | Sep 28, 2021 | Pfizer |
| NCT03181893 | Phase 2 | Oct 10, 2017 | Pfizer |
| NCT02766621 | Phase 1 | May 27, 2016 | Pfizer |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 7 | 7 | 3 | 2016 |
1 organizations
Page 1 / 1